Curasight: Opsummering fra fysisk investorseminar
Curasight var repræsenteret af CEO Ulrich Krasilnikoff. Udover en generel introduktion til selskabet og en opdatering på pipeline og hvilke milestones investorerne skal fokuserer på i fremtiden, gav Ulrich Krasilnikoff en god gennemgang af den igangværende kapitalforhøjelse.
Se præsentationen (PDF) her: Curasight investor præsentation
Disclaimer: HC Andersen Capital modtager betaling fra Curasight for en Digital IR/Corporate Visibility abonnementsaftale. /Claus Thestrup kl. 14:20 d. 20-09-2024
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read more on company page